12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TZP-102: Preliminary Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 201 patients with Type I or II diabetes and a confirmed diagnosis of gastroparesis showed that once-daily 10 and 20 mg oral TZP-102 each missed the primary endpoint of reducing GSDD composite score from baseline during the last 2 weeks of...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >